Download Important New Information for the IRB regarding

Reporting Update for Temple University Serious Adverse Event
All Serious Adverse Events occurring to any subject enrolled in a research
trial at Temple University MUST be reported to the TIRB. This may be
different than what the Sponsor or Sponsor Agent requests.
Serious Adverse Event (SAE): Serious adverse events are defined by
regulatory criteria and include any of the following:
 Any hospital admission (unless hospitalization is preplanned).
 Unanticipated or life-threatening drug reaction including but not limited
to one that necessitates discontinuation of study participation or that
results in death
 Congenital anomaly occurring in the offspring of a research participant
who had taken a study drug
 Exceeding the nature, severity, or frequency described in the
investigator’s brochure or protocol
 Prolongs a stay in a health care facility
 Significant, persistent, or permanent harm or disability, either physical
or psychological
 Death
This information is in addition to the information as presented below:
Important New Information for the IRB regarding Adverse Events Reporting
This will have an effect on reports to the TIRB, WIRB and FIRB
Federal Regulations at 21CFR 5.6108(b)(1) AND 45CFR 46.103(b)(5) require the
IRB to “follow written procedures for ensuring prompt reporting to the IRB … any
unanticipated problems involving risks to human subjects and others …
Whereas Temple University performs FDA regulated research and receives
funding from the NIH and in accord with the University FederalWide Assurance
provided by OHRP – Temple is required to follow all applicable reporting
requirements across all agencies.
Adverse Event Reporting is among the REQUIRED obligations undertaken by
each PI when research is approved by the IRB, and/or under the TU OHRP
Assurance, and/or funded by the government, and/or regulated by the FDA. This
means that all research performed at TU must follow the REQUIRED reporting of
unanticipated problems which are defined as any incident, experience, or
outcome that meets all of the following criteria:
1
1. unexpected (in terms of nature, severity, or frequency) given (a) the
research procedures that are described in the protocol-related documents,
such as the IRB-approved research protocol and informed consent
document, or the Investigator Brochure; and (b) the characteristics of the
subject population being studied;
2. related or possibly related to participation in the research (possibly related
means there is a reasonable possibility that the incident, experience, or
outcome may have been caused by the drugs, devices or procedures
involved in the research); and
3. suggests that the research places subjects or others at a greater risk of
harm (including physical, psychological, economic, or social harm) than
was previously know or recognized.
All reports to the IRB of unanticipated problems should explain clearly why the
event is “unanticipated” and clearly explain why the event represents a “problem
involving risks to human subjects or others.”
The IRBs expects reports to the IRB of unanticipated problems to include a
corrective action plan to address the issue, or written justification for why none is
provided. Unnecessary or incomplete reporting of problems that do not meet the
criteria as outlined above may impair the IRB’s ability to review and respond in a
timely manner to actual situations where subject rights, welfare or safety may be
in question or threatened.
Adverse events are any untoward or unfavorable medical occurrence in human
subjects, including any abnormal sign (for example, abnormal physical exam or
laboratory finding), symptom, or disease, temporally associated with the subject’s
participation in the research, whether or not considered related to the subject’s
participation in the research.
FDA guidance documents recognize that:
1. “individual adverse event reports generally require an evaluation of their
relevance and significance to the study, including an evaluation of other
adverse events, before they can be considered to be an unanticipated
problem,” and
2. “all reports to the IRB of unanticipated problems should explain clearly
why the event described represents a ‘problem’ for the study and why it is
“unanticipated.”
The FDA believes that reports that lack such evaluation should not be provided
to the IRB.
The reporting requirements for the IRBs may differ from the reporting
requirements outlined by individual sponsors. Only report to the IRBs adverse
events that in the opinion of the investigator may represent unanticipated
problems involving risks to other subjects in the research.
2
A. For adverse events that are determined to be unanticipated problems
occurring at TU:
Investigators are required to report adverse events that fit the following criteria
within 10 working days of the time the investigator becomes aware of them:
1. unexpected (in terms of nature, severity, or frequency) given (a) the
research procedures that are described in the protocol-related documents,
such as the IRB-approved research protocol and informed consent
document, or the Investigator
Brochure; and (b) the characteristics of the subject population being
studied;
2. related or possibly related to participation in the research (possibly related
means there is a reasonable possibility that the incident, experience, or
outcome may have been caused by the drugs, devices or procedures
involved in the research); and
3. suggests that the research places subjects or others at a greater risk of
harm (including physical, psychological, economic, or social harm) than
was previously know or recognized.
If the adverse event is clearly not related to the study drug, device, procedures,
or washout process, it would not represent risk to other subjects in the research
or a “problem” for the study and does not need to be reported to the TIRB, WIRB
or FIRB.
The current TU adverse reporting system should be employed following the new
guidance. ADDITIONALLY, reporters are requested to provide the following
information in the cover letter:
1. AE Description/Treatment/Outcome (including relevant dates):
2. Pertinent subject history:
3. Why the event is considered “unanticipated”?
4. Why the event is considered “problem involving risks to human subjects
and others”?
5. What changes are proposed to the consent form and/or the protocol in
order to protect the rights, welfare and safety of the research subjects? If
none are proposed, provide the rationale why changes are not needed.
When reporting to the WIRB or the FIRB be sure to use their most current
reporting procedures. Visit the appropriate WIRB or FIRB websites for the
current forms and directions. (The decision tree will be updated when materials
are constructed and available).
B. For adverse events that are determined to be unanticipated problems
that did not occur at TU (non-site adverse event reports such and IND,
MedWatch, and others):
3
The IRBs will accept non-site adverse event reports submitted by investigators
and from sponsors on behalf of investigators, if, in accord with 21CFR 312.32,
 the event described is both serious and unexpected.
 the report identifies all previous safety reports concerning similar adverse
experiences,
 the report analyzes the significance of the current adverse experience in
light of the previous reports,
and
 the report outlines a corrective action plan.
The IRBs will not accept non-site adverse events that do not identify all previous
safety reports concerning similar adverse experiences analyze the significance of
the current adverse experience with regard to the pervious reports and outline a
proposed corrective action plan.
If the sponsor, CRO or SMO does not submit non-site adverse events that are
determined to be unanticipated problems to the IRBs – the investigator is
required to submit them, along with the required explanation outlined above,
within 10 days of the date of receiving such reports.
The IRBs recognize the for multicenter studies, the sponsor is in a better position
to process and analyze adverse events information for the entire study, and to
assess whether an occurrence is both “unanticipated” and a “problem” for the
study. You may rely on the sponsor’s assessment and provide to the IRBs a
report of the unanticipated problem prepared by the sponsor.
C. Instructions for reporting unanticipated problems that are not adverse
events:
 Unanticipated problems that do not fit the definition of an adverse event,
but which may, in the opinion of the investigator, involve risk to the
subject, affect others in the research study, or significantly impact the
integrity of research data. As an example, report occurrences of breaches
of confidentiality, accidental destruction of study records, or unaccountedfor study drug.
 Unplanned protocol deviations/violations that have already occurred, that
may adversely affect the rights, safety or welfare of subjects or the
integrity of the research data, AND for which you did not seek IRB preapproval.
Report occurrences within 10 days of becoming aware of them. The current TU
adverse reporting system SHOULD NOT be employed for this reporting.
Reporters are requested to provide the following information in the cover letter:
4
1. Describe the problem:
2. Why is the event considered “unanticipated”?
3. Why is the event considered a “problem involving risks to human subjects
or others”?
4. Were there adverse effects to those involved? If yes, describe.
5. Describe what action is taken or will be taken to prevent recurrence:
When reporting to the WIRB or the FIRB be sure to use their most current
reporting procedures. Visit the appropriate WIRB or FIRB websites for the
current forms and directions. (The decision tree will be updated when materials
are constructed and available).
Planned protocol deviations that may adversely affect the rights, safety or welfare
of subjects or the integrity of the research data should be submitted to the IRBs
for review and approval prior to implementation except where necessary to
eliminate immediate hazards to the human subjects following:
45CFR 46.103(b)(4); 21
CFR 56.108(a)(4)
ICH 3.3.7
Planned protocol deviations should be requested via memorandum to the TIRB.
When reporting to the WIRB or the FIRB be sure to use their most current
reporting procedures. Visit the appropriate WIRB or FIRB websites for the
current forms and directions. (The decision tree will be updated when materials
are constructed and available).
5